This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kass, D. A. Search for Related Content PubMed PubMed Citation Articles by Kass, D. A. Related Collections Biochemistry and metabolism Other myocardial biology Other heart failure Heart failure - basic studies Hypertrophy Related Article

(Circulation. 2007;116:233-235.)
© 2007 American Heart Association, Inc.

Editorial

Hypertrophied Right Hearts Get Two for the Price of One

Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3?

David A. Kass, MD

From Johns Hopkins Medical Institutions, Baltimore, Md.

Correspondence to David A. Kass, MD, Division of Cardiology, Ross 835, Johns Hopkins Medical Institutions, 720 Rutland Ave, Baltimore, MD 21205. E-mail dkass@jhmi.edu

Key Words: Editorials • hypertrophy • nucleotides, cyclic • pharmacology • cyclic nucleotide phosphodiesterases, type 5 • pulmonary heart disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Phosphodiesterase type 5 (PDE5) was first discovered in the mid 1970s, not as a PDE but rather as a binding protein for cGMP.¹ Shortly thereafter, it became clear that this protein also had cGMP-selective PDE activity, and cGMP-binding to domains in the N-terminus (GAF domains) regulated its enzymatic activity.² PDE5 gained more attention in the mid 1980s when its role in modulating vascular tone was revealed.³ Pharmacologists at Pfizer considered it a potential drug for hypertension or coronary heart disease, which led to the development of UK-92,480 (sildenafil), a selective and potent PDE5 inhibitor. Although the desired cardiovascular responses were unimpressive, the phase I studies revealed a now-famous side effect that was quite popular among the trial participants. This ultimately led to development of PDE5 inhibitors for erectile dysfunction.⁴ Cardiac data collected to confirm drug safety found little impact of these agents on the heart.^5–7 Gene and protein PDE5 expression was low, and even whether the enzyme was in myocytes was controversial.⁸ Limited functional analysis obtained largely under rest conditions suggested negligible effects.⁷

Article p 238

The plot thickened in the late 1990s when our laboratory reported that PDE5 (or PDE5A) appeared to be present and active in canine myocardium and isolated myocytes and that, in normal animals, selective PDE5 inhibition blunted ß-adrenergic stimulation.⁹ Work subsequently reported by Kukreja and colleagues¹⁰ and Das et al¹¹ revealed that PDE5 inhibition preconditioned ischemic hearts and was cytoprotective (antiapoptotic) in isolated myocytes. In mice, PDE5 inhibitors blunt adrenergic stimulation in normal myocytes, an . . . [Full Text of this Article]

Related Article:

Issue Highlights
Circulation 2007 116: 231. [Extract] [Full Text]

This article has been cited by other articles:

				S. Rich The Effects of Vasodilators in Pulmonary Hypertension: Pulmonary Vascular or Peripheral Vascular? Circ Heart Fail, March 1, 2009; 2(2): 145 - 150. [Full Text] [PDF]

				M. J. Semigran Phosphodiesterase Type 5 Inhibition: A Support of the Left Ventricular Assist Device Bridge to Transplant Circ Heart Fail, November 1, 2008; 1(4): 211 - 212. [Full Text] [PDF]

				S. R. Goldsmith Type 5 Phosphodiesterase Inhibition in Heart Failure: The Next Step J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2145 - 2147. [Full Text] [PDF]

				D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]